AJP - Lung Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 291: L1068-L1078, 2006. First published July 7, 2006; doi:10.1152/ajplung.00093.2006
1040-0605/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/5/L1068    most recent
00093.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kunig, A. M.
Right arrow Articles by Abman, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kunig, A. M.
Right arrow Articles by Abman, S. H.

Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia

Anette M. Kunig, Vivek Balasubramaniam, Neil E. Markham, Gregory Seedorf, Jason Gien, and Steven H. Abman

Pediatric Heart Lung Center, Department of Pediatrics, University of Colorado Health Sciences Center, The Children's Hospital, Denver, Colorado

Submitted 13 March 2006 ; accepted in final form 5 July 2006

Recent studies suggest that VEGF may worsen pulmonary edema during acute lung injury (ALI), but, paradoxically, impaired VEGF signaling contributes to decreased lung growth during recovery from ALI due to neonatal hyperoxia. To examine the diverse roles of VEGF in the pathogenesis of and recovery from hyperoxia-induced ALI, we hypothesized that exogenous recombinant human VEGF (rhVEGF) treatment during early neonatal hyperoxic lung injury may increase pulmonary edema but would improve late lung structure during recovery. Sprague-Dawley rat pups were placed in a hyperoxia chamber (inspired O2 fraction 0.9) for postnatal days 2–14. Pups were randomized to daily intramuscular injections of rhVEGF165 (20 µg/kg) or saline (controls). On postnatal day 14, rats were placed in room air for a 7-day recovery period. At postnatal days 3, 14, and 21, rats were killed for studies, which included body weight and wet-to-dry lung weight ratio, morphometric analysis [including radial alveolar counts (RAC), mean linear intercepts (MLI), and vessel density], and lung endothelial NO synthase (eNOS) protein content by Western blot analysis. Compared with room air controls, hyperoxia increased pulmonary edema by histology and wet-to-dry lung weight ratios at postnatal day 3, which resolved by day 14. Although treatment with rhVEGF did not increase edema in control rats, rhVEGF increased wet-to-dry weight ratios in hyperoxia-exposed rats at postnatal days 3 and 14 (P < 0.01). Compared with room air controls, hyperoxia decreased RAC and increased MLI at postnatal days 14 and 21. Treatment with VEGF resulted in increased RAC by 181% and decreased MLI by 55% on postnatal day 14 in the hyperoxia group (P < 0.01). On postnatal day 21, RAC was increased by 176% and MLI was decreased by 58% in the hyperoxia group treated with VEGF. rhVEGF treatment during hyperoxia increased eNOS protein on postnatal day 3 by threefold (P < 0.05). We conclude that rhVEGF treatment during hyperoxia-induced ALI transiently increases pulmonary edema but improves lung structure during late recovery. We speculate that VEGF has diverse roles in hyperoxia-induced neonatal lung injury, contributing to lung edema during the acute stage of ALI but promoting repair of the lung during recovery.

bronchopulmonary dysplasia; lung development; vascular endothelial growth factor; alveolarization; angiogenesis



Address for reprint requests and other correspondence: A. Kunig, Pediatric Heart Lung Center, Univ. of Colorado School of Medicine and The Children's Hospital, Pediatrics, Mail Stop 8317, PO Box 6511, Aurora, CO 80045 (e-mail: anette.kunig{at}uchsc.edu)




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
V. Bhandari, R. Choo-Wing, C. G. Lee, K. Yusuf, J. H. Nedrelow, N. Ambalavanan, H. Malkus, R. J. Homer, and J. A. Elias
Developmental Regulation of NO-Mediated VEGF-Induced Effects in the Lung
Am. J. Respir. Cell Mol. Biol., October 1, 2008; 39(4): 420 - 430.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. Gien, G. J. Seedorf, V. Balasubramaniam, N. Markham, and S. H. Abman
Intrauterine Pulmonary Hypertension Impairs Angiogenesis In Vitro: Role of Vascular Endothelial Growth Factor Nitric Oxide Signaling
Am. J. Respir. Crit. Care Med., December 1, 2007; 176(11): 1146 - 1153.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. R. Grover, T. M. Asikainen, J. P. Kinsella, S. H. Abman, and C. W. White
Hypoxia-inducible factors HIF-1{alpha} and HIF-2{alpha} are decreased in an experimental model of severe respiratory distress syndrome in preterm lambs
Am J Physiol Lung Cell Mol Physiol, June 1, 2007; 292(6): L1345 - L1351.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
B. Thebaud and S. H. Abman
Bronchopulmonary Dysplasia: Where Have All the Vessels Gone? Roles of Angiogenic Growth Factors in Chronic Lung Disease
Am. J. Respir. Crit. Care Med., May 15, 2007; 175(10): 978 - 985.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.